Provided by Tiger Fintech (Singapore) Pte. Ltd.

DiaMedica Therapeutics Inc.

5.16
-0.0500-0.96%
Volume:71.91K
Turnover:373.40K
Market Cap:220.64M
PE:-9.32
High:5.34
Open:5.25
Low:5.11
Close:5.21
Loading ...

Company Profile

Company Name:
DiaMedica Therapeutics Inc.
Exchange:
NASDAQ
Establishment Date:
2000
Employees:
19
Office Location:
301 Carlson Parkway,Suite 210,Minneapolis,Minnesota,United States
Zip Code:
55305
Fax:
- -
Introduction:
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Directors

Name
Position
Richard Pilnik
Chairman of the Board and Independent Director
Rick Pauls
President and Chief Executive Officer, Director
James Parsons
Independent Director
Michael Giuffre
Independent Director

Shareholders

Name
Position
Rick Pauls
President and Chief Executive Officer, Director
Scott Kellen
Chief Financial Officer and Secretary
Harry Alcorn
Chief Medical Officer
Richard Pilnik
Chairman of the Board and Independent Director
Sydney Gilman
Vice President, Regulatory Affairs